• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·SYUP
Share

Anbc, Inc. Stocks

$ 0Last Updated 30.07.2026

Issuer Rating

Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

$ 15921

$ 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Shanghai Yutong Pharma, Inc., a company based in Shanghai, China, specializes in the development, manufacturing, and distribution of both traditional Chinese herbal remedies and cutting-edge biological pharmaceuticals within the People's Republic of China. Their diverse product portfolio addresses a wide range of health concerns. Noteworthy offerings include Qilisheng, crafted to strengthen the immune system and promote overall vitality. Oral solutions such as Qi-ju-di-huang are formulated to support kidney and liver function, while Qing-re-jie-du serves to reduce fever and alleviate heat. Sheng-mai-yin is designed to conserve vital energy and replenish bodily fluids, and Xiao-qing-long provides relief from coughs and difficulty breathing. The company also produces various syrups: Shen-bao targets the treatment of impotence and spermatorrhoea; Ban-xia offers cough suppression; and Gan-mao-zhi-ke combats symptoms of the flu, coughs, and nasal congestion. Further herbal preparations encompass Ban-lan-gen for common cold and influenza relief; Gan-mao-qing-re, which helps to mitigate minor body aches, pains, and fever; Huang-dan-yin-chen, utilized in managing jaundice and infectious hepatitis; and Liu-shen-qu, prescribed for instances of vomiting and dysentery. These pharmaceutical goods are supplied to distributors via a wholesale model.

Company Valuation

Greatly undervalued
7/7

Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. In particular, the stock is underpriced on P/E, undervalued on P/F

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

01.08.2026 16:01

Small-Cap Highlights: Cathie Wood's Investments, the Sale of Forte Biosciences, and the CBIZ Deal

01.08.2026 13:01

Apple's Short-Lived Triumph, Non-Banks Battle for Colombia, and a Dinosaur Worth Millions of Dollars

01.08.2026 04:17

Not a White Knight: How the “Savior” of “AI-Nostradamus” Makes Money by Sensing Trouble

01.08.2026 03:08

Trump Ordered New Strikes Against Iran — WSJ

01.08.2026 02:07

The Nasdaq Composite had its worst July in 20 years due to a plunge in chipmaker stocks

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026